BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hall JA, Salgado R, Lively T, Sweep F, Schuh A. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. The Lancet Oncology 2014;15:e184-93. [DOI: 10.1016/s1470-2045(13)70607-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer 2020;6:15. [PMID: 32436923 DOI: 10.1038/s41523-020-0155-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 De Ruysscher D, Defraene G, Ramaekers BLT, Lambin P, Briers E, Stobart H, Ward T, Bentzen SM, Van Staa T, Azria D, Rosenstein B, Kerns S, West C. Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiother Oncol 2016;121:440-6. [PMID: 27979370 DOI: 10.1016/j.radonc.2016.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine 2015;2:264-71. [PMID: 26137564 DOI: 10.1016/j.ebiom.2015.02.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
4 Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J 2016;22:156-64. [PMID: 27341592 DOI: 10.1097/PPO.0000000000000190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
5 Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Societal challenges of precision medicine: Bringing order to chaos. Eur J Cancer 2017;84:325-34. [PMID: 28865260 DOI: 10.1016/j.ejca.2017.07.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
6 Yee LM, Lively TG, McShane LM. Biomarkers in early-phase trials: fundamental issues. Bioanalysis 2018;10:933-44. [PMID: 29923753 DOI: 10.4155/bio-2018-0006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
7 Lacombe A, Carafa V, Schneider S, Sticker-Jantscheff M, Tornillo L, Eppenberger-Castori S. Re-Punching Tissue Microarrays Is Possible: Why Can This Be Useful and How to Do It. Microarrays (Basel) 2015;4:245-54. [PMID: 27600223 DOI: 10.3390/microarrays4020245] [Reference Citation Analysis]
8 Leite KRM, Barrios CH, Buzaid AC, Gagliato D, Gobbi H, Soares F. Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-021-00092-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Miglietta F, Griguolo G, Guarneri V, Dieci MV. Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. Oncologist 2019;24:e1055-69. [PMID: 31444294 DOI: 10.1634/theoncologist.2019-0197] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
10 Clump DA, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res 2019;25:1441-2. [PMID: 30413524 DOI: 10.1158/1078-0432.CCR-18-3078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Brown MA, Li Z, Cao KL. Biomarker development for axial spondyloarthritis. Nat Rev Rheumatol 2020;16:448-63. [PMID: 32606474 DOI: 10.1038/s41584-020-0450-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
12 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 10.5] [Reference Citation Analysis]
13 Tembuyser L, Dequeker EM. Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers. Virchows Arch 2016;468:31-41. [PMID: 26306715 DOI: 10.1007/s00428-015-1839-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lim SJ, Gurusamy K, O'Connor D, Shaaban AM, Brierley D, Lewis I, Harrison D, Kendall TJ, Robinson M. Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation. J Pathol Clin Res 2021;7:191-202. [PMID: 33635586 DOI: 10.1002/cjp2.199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Pang H, Wang X. Statistical aspect of translational and correlative studies in clinical trials. Chin Clin Oncol 2016;5:11. [PMID: 26932435 DOI: 10.3978/j.issn.2304-3865.2014.07.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]